Here, we propose to evaluate the safety, efficacy, and pharmacodynamics of inhaled cyclosporine for the treatment of BO
Drug DetailsLiposomal Cyclosporine A for inhalation (L-CsA-i) is a true liposome of cyclosporine A designed for inhaled delivery to the lungs (administered via the high
Methods: We conducted a single-center, randomized, double-blind, placebo-controlled trial of inhaled cyclosporine initiated within six weeks after transplantation
Of the 2,396 patients who received ZETIA in clinical trials, 669 (28%) were 65 years of age and older, and 111 (5%) were 75 years of age and older
194: Inhaled Cyclosporine Is Well Tolerated in the CYCLIST Clinical Trial - The Journal of Heart and Lung Transplantation Study RIN-PF-301 is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute FVC in subjects with IPF over a 52-week period
We conducted a single-center, randomized, double-blind, placebo-controlled trial of inhaled cyclosporine initiated within six weeks after transplantation and given in addition to systemic Inhaled ciclosporin
Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery
However, an independent analysis of pulmonary The aerosol size distribution produced at the conditions utilized during clinical trials is provided in Fig
The size of the aerosol delivered using this compressor–nebulizer system will vary inversely and linearly
7 years in the standard of care group
In humans, numerous clinical trials have shown that inhaled cyclosporine can prevent or ameliorate histological rejection and improve lung function [18–28]
The fate and effects of inhaled cyclosporine A (CsA) are considered after deposition on the lung surface
Traditional rescue therapies have proved only modestly successful